Phase Ia randomised, double-blind, placebo-controlled trial of FOR-6219 in healthy postmenopausal women
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2018
At a glance
- Drugs FOR-6219 (Primary)
- Indications Endometriosis
- Focus Adverse reactions
- Sponsors Forendo Pharma
- 04 Jul 2018 Status changed from planning to recruiting, according to a Forendo Pharma media release.
- 04 Jul 2018 According to a Forendo Pharma media release, UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the clinical trial authorisation. Results are expected at end of 2018.
- 23 Mar 2018 New trial record